Herzog Fox & Neeman represented Nazareth-based AlphaOmega, creators and manufacturers of brain-stimulation devices for surgery in a $7 million JV

**IMPORTANT CLARIFICATION** Further to our earlier client update and following recent publications in the Israeli news alleging a wide interpretation

Herzog Fox & Neeman Partners Yair Geva, Tomer Farkash, Dan Sharot, and Ofer Granot, together with Associate Michal Shirin,  represented Israeli biopharmaceutical company Entera Bio

Herzog Fox & Neeman Represents Entera Bio in $270m Amgen Licensing Deal

Herzog, Fox & Neeman acted for 888 US Inc., a wholly owned subsidiary of 888 Holdings Plc, in its acquisition

Herzog Fox & Neeman Represents 888 in Acquisition of AAPN from Avenue OLG Entertainment

Herzog Fox & Neeman represented CodeMonkey Studio Inc. in their acquisition by TAL Education Group.  CodeMonkey’s specialty is game-like computer

Herzog Fox & Neeman Represents CodeMonkey Studio Inc. in Buy-Out

We are pleased to present the latest edition of our monthly Technology & Regulation Client Update, which includes a variety of

On November 28, 2018 the Protection of Privacy Authority (the “PPA”) issued a statement of opinion reflecting its position, according

Client Update | Collection of Names and Email Addresses Constitutes a “Database”

In a precedential ruling, a Delaware Court has allowed Fresenius to withdraw from a $4.75 billion acquisition of Acorn Pharmaceuticals

The Start-Up’s Worst Nightmare: Precedential US Ruling on Exits

As of January 2018, the Israeli Tax Authority (hereinafter: “the ITA”) has replaced the Custom Administration’s foreign trade system with

This update concerns two significant and inter-related steps recently taken by the Israeli Antitrust Commissioner intended to reduce the regulatory

Client Update | Towards a reform in Competition Law

Herzog Fox & Neeman advised Linse Capital in a $63 million investment in Hod HaSharon-based Valens. Linse was advised by Hanan